IL-23 Recombinant Antibody

$293T (H) cells were treated with or without LPS and IFN (40ng\/mL) for 24 h, BFA (300ng\/mL) for 24 h, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with IL-23 polyclonal antibody, unconjugated (bsm-61831R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

293T (H) cells were treated with or without LPS and IFN (40ng\/mL) for 24 h, BFA (300ng\/mL) for 24 h, 25 \u03bcg total protein per lane of cell lysates (see on figure) probed with IL-23 polyclonal antibody, unconjugated (bsm-61831R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

Reactivity

Human

Overview
Catalog #	bsm-61831r
Product Name	IL-23 Recombinant Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human IL 23A
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	51561
Swiss Prot	Q9NPF7
Subcellular location	Secreted
Synonyms	IL 23A; IL 23p19; IL12B; IL23; Il23a; IL23P19; P19; SGRF.
Background	Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity.Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4.
Application Dilution
WB	1:500-2000